/

Società

Ga

Non verificato

Gan & Lee Pharmaceuticals

Di cosa scriviamo

BiologiaFarmaceuticaFitnessSaluteSanità

11 comunicati stampa

Guarda tutti i comunicati

Press Release cover image

09/04/2026

Salute

Fitness

Mercato del lavoro

Legge/Diritto

Fisco/Tributi

Medicina - Varie

Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide

Fonte

Gan & Lee Pharmaceuticals

Emittente

1.00

0

Press Release cover image

31/03/2026

Salute

Fitness

Medicina - Varie

Gan & Lee Pharmaceuticals' Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2

Fonte

Gan & Lee Pharmaceuticals

Emittente

1.00

0

10/03/2025

Farmaceutica

Sanità

Economia

Start-up

Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity

Fonte

Gan & Lee Pharmaceuticals

Emittente

1.00

0

Press Release cover image

18/12/2024

Farmaceutica

Banca

Sanità

Scienza

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 head-to-head with Tirzepatide clinical trial)

Fonte

Gan & Lee Pharmaceuticals

Emittente

1.00

0

Press Release cover image

12/11/2024

Farmaceutica

Sanità

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks

Fonte

Gan & Lee Pharmaceuticals

Emittente

1.00

0

Press Release cover image

11/11/2024

Farmaceutica

Sanità

ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults

Fonte

Gan & Lee Pharmaceuticals

Emittente

1.00

0

Press Release cover image

15/10/2024

Farmaceutica

Sanità

Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies

Fonte

Gan & Lee Pharmaceuticals

Emittente

1.00

0

Press Release cover image

14/09/2024

Farmaceutica

Sanità

Biologia

Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)

Fonte

Gan & Lee Pharmaceuticals

Emittente

1.00

0

Press Release cover image

22/07/2024

Farmaceutica

Sanità

Biologia

Gan & Lee Pharmaceuticals' Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

Fonte

Gan & Lee Pharmaceuticals

Emittente

1.00

0

Press Release cover image

22/06/2024

Farmaceutica

Sanità

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions

Fonte

Gan & Lee Pharmaceuticals

Emittente

1.00

0

Seguaci

0

Compatibilità

0